Navigation Links
Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
Date:3/31/2011

WALTHAM, Mass., March 31, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced 11 posters on entinostat, an oral, highly selective, class I histone deacetylase (HDAC) inhibitor, will be presented at the 102nd Annual American Association for Cancer Research meeting April 2 to April 6 in Orlando, FL.

"The breadth of exciting data being presented at AACR provides additional insight into the opportunities for Syndax to build out our entinostat development program," said Joanna Horobin, president and chief executive officer of Syndax. "The AACR presentations add to the growing body of evidence supporting the potential for entinostat in solid tumors including the promising results with entinostat in combination with Tarceva® in advanced non-small-cell lung cancer which were presented at the end of last year. Recently we completed our randomized, placebo-controlled phase 2 clinical trial in metastatic breast cancer which will be presented at a scientific conference later this year and are aggressively moving forward with a pivotal program in this patient population." The following posters will be presented Monday, April 4: Time:

8:00 AM to 12:00 PM EDT: Presentation #:

1146 Title:

Multiple HDAC inhibitors (HDACi) reduce the expression of the oncogenic miR-17~92 cluster; a pan HDACi class effect Location:

Exhibit Hall A4-C, Poster Section 7 Time:

8:00 AM to 12:00 PM EDT: Presentation #:

1792 Title:

Selective class I HDAC inhibitor SNDX-275 enhances anti-tumor survivin vaccine therapy by suppressing regulatory T cells in a model of prostate cancer Location:

Exhibit Hall A4-C, Poster Section 32 Time:

1:00 to 5:00 PM EDT: Presentation #:

2018 Title:

Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model Location:

Exhibit Hall A4
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
2. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
3. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
4. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
5. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
6. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
7. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
8. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
9. Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression
10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
11. Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-Code for Xeomin® (incobotulinumtoxinA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DIEGO , Sept. 18, 2014  Halozyme ... announced that the U.S. Food and Drug Administration ... enrollment and dosing of PEGPH20 in SWOG,s ongoing ... designed to evaluate Halozyme,s investigational drug PEGPH20 (PEGylated ... chemotherapy (mFOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma.  ...
(Date:9/18/2014)... -- Australian biomarker discovery company Minomic International Ltd will ... prostate cancer screening test, planning to achieve US Food ... Minomic,s proprietary MiStat™ technology is a screening assay ... known as the MIL-38 antigen. This biomarker is present ... Researchers at 11 leading urology centres in ...
(Date:9/18/2014)... , Sept. 18, 2014 /CNW/ - A new expert panel ... Canada , released today by the Council ... and effective medicines for children. Each year about half ... use at least one prescription drug. Much of this ... the authorized use), creating potential health risks. ...
Breaking Medicine Technology:SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3
... , BEDFORD, Mass., Aug. 19 Holo ... (Nasdaq: HOLX ), a leading developer, manufacturer and supplier of ... healthcare needs of women, today announced the publication of the first of ... both symptomatic and asymptomatic pregnant women at risk for preterm birth. The ...
... , JAMESBURG, N.J., Aug. 19 Phytomedics Inc. today ... 2b clinical trial with an extract of Tripterygium wilfordii Hook F ... in the August 18, 2009 issue of the Annals of Internal ... article entitled "Comparison of Tripterygium wilfordii Hook F versus ...
Cached Medicine Technology:Study Links Fetal Fibronectin Testing with Changes in Management Decisions for Symptomatic and Asymptomatic Women at Risk for Preterm Birth 2Study Links Fetal Fibronectin Testing with Changes in Management Decisions for Symptomatic and Asymptomatic Women at Risk for Preterm Birth 3Study Links Fetal Fibronectin Testing with Changes in Management Decisions for Symptomatic and Asymptomatic Women at Risk for Preterm Birth 4Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis 2Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis 3
(Date:9/18/2014)... Texas Physical Therapy Specialists (TexPTS) is proud ... Physicians Association (HPA) Friends and Family Golf tournament ... The tournament, which will take place at TopGolf from ... scholarships through three golf challenges, “Top Scramble”, “Top Score”, ... is provided at the event and there will be ...
(Date:9/18/2014)... 18, 2014 After years of shooting at ... firing range berms were saturated with lead, which increased the ... in the berm and send metal fragments back at the ... splashback, and the greater the potential for injury to officers. ... to remove lead from the range environment. , ...
(Date:9/18/2014)... 18, 2014 Sutter Health’s California Pacific ... of Dolby Laboratories, by naming the Ray Dolby Brain ... Ray Dolby provided a founding gift of $21 million ... provides services to patients and families suffering from Alzheimer’s, ... have been treated at the center since its opening ...
(Date:9/18/2014)... On August 23, the HearStrong Foundation ... Service Award for his contributions to the deaf and ... Retired Players Association (NBRPA) Legends World Sports Conference in ... in 1977, Glenn would go on to play for ... Hawks, and the Milwaukee Bucks throughout his ten-year career ...
(Date:9/18/2014)... MD Complete , the breakthrough ... prescription, announced today that SHAPE Magazine has named ... Peel” in its annual Beauty Awards. The issue is ... products as tested by SHAPE’s expert team. , SHAPE ... Among the thousands of beauty products launched every year, ...
Breaking Medicine News(10 mins):Health News:Texas Physical Therapy Specialists Sponsoring HPA Friends & Family Golf Tournament 2Health News:Firing Range Safety is Ohio DOC Priority 2Health News:Firing Range Safety is Ohio DOC Priority 3Health News:Sutter Health’s CPMC announces Ray Dolby Brain Health Center 2Health News:Sutter Health’s CPMC announces Ray Dolby Brain Health Center 3Health News:The HearStrong Foundation Recognizes Mike “Stinger” Glenn with the Distinguished Service Award at the 2014 Legends World Sports Conference 2Health News:The HearStrong Foundation Recognizes Mike “Stinger” Glenn with the Distinguished Service Award at the 2014 Legends World Sports Conference 3Health News:MD Complete Wins Shape Beauty Award for Best Peel 2
... Accounts; Membership in ECP Global Communication International NetworkNEW ... www.feintuchcommunications.com ), a strategic relations firm ... Feintuch, has opened for business with offices at ... http://www.newscom.com/cgi-bin/prnh/20090406/NY94367LOGO )Mr. ...
... for Medical Benefits, Movement to Direct Contracting for ... HealthLeaders-InterStudyNASHVILLE, Tenn., April 6 HealthLeaders-InterStudy, the leading ... between January 2008 and July 2008 enrollment in ... with a pharmacy benefit manager (PBM), also known ...
... Michael Paddock, CEO of Grants Office, LLC and a ... for on-camera and telephone interviews.Over the past several months, ... of knowledge and resources relating to the American Recovery ... knowledge of the various facets of ARRA funding (in ...
... April 6 The Quantum Group, Inc. (NYSE Amex: ... a Healthcare Services Organization (HSO), announced today that PWeR(TM) ... information platform and IBM hosted solution, is presenting in ... and Management Systems Society) Conference. The HIMSS09 conference ...
... those diagnosed with autism have underlying medical disorders that ... improvementATLANTA, April 6 A child is diagnosed with ... is more common in American children than cancer, diabetes, ... Control (CDC) estimates that one in every 94 boys ...
... Breakthrough Study Led by USC and Mayo ... Older adults can significantly improve their memory and performance ... according to a study published today in The Journal ... of 487 healthy older adults was led by researchers ...
Cached Medicine News:Health News:Feintuch Communications Launches as Independent Strategic Relations Firm 2Health News:Feintuch Communications Launches as Independent Strategic Relations Firm 3Health News:Feintuch Communications Launches as Independent Strategic Relations Firm 4Health News:Enrollment in Employer-Contracted Pharmacy Benefit 'Carve-Out' Increased by More than Six Million Lives 2Health News:Grants Office CEO Available for Media Interviews on Stimulus Funding 2Health News:PWeR(TM) Presenting at HIMSS Conference in Chicago 2Health News:PWeR(TM) Presenting at HIMSS Conference in Chicago 3Health News:PWeR(TM) Presenting at HIMSS Conference in Chicago 4Health News:Alarming Rise in Autism Brings Hundreds of Parents, Researchers and Clinicians Together from Around the World to Atlanta April 17-19, 2009 2Health News:Computerized Brain Exercise Improves Memory 2
Inquire...
... The Trinity Biotech Captia™ Mumps IgG ... the detection and quantitative determination of IgG ... Individual serum specimens may be used for ... acute and convalescent, may be used to ...
... AUTOMATION, INC. (DAI) Mumps IgG ... intended for the detection and ... to Mumps virus in human ... be used for the determination ...
... Corporation announced the launch of the ... first bi-directional cooled-tip catheter available in the ... offers physicians the benefits of cooled ablation ... the Boston Scientific Blazer(R) catheter platform. ,Cooled ...
Medicine Products: